Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Vitek

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
European Journal of Applied Physiology and Occupational Physiology|January 1, 1980
Changes in maximal aerobic power, aerobic capacity, and muscle enzyme activities at two stages of the annual training cycle in ski-runnersS Sprynarová, A Bass, E Macková, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|March 15, 1977
Urinary cyclic AMP and post-traumatic acute renal failureV Vitek, P H Gold, W Gill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
A phase I and pharmacokinetic study of tallimustine [PNU 152241 (FCE 24517)] in patients with advanced cancerG R Weiss, I Poggesi, M Rocchetti, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
European Journal of Applied Physiology and Occupational Physiology|January 1, 1980
Changes in maximal aerobic power, aerobic capacity, and muscle enzyme activities at two stages of the annual training cycle in ski-runnersS Sprynarová, A Bass, E Macková, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|March 15, 1977
Urinary cyclic AMP and post-traumatic acute renal failureV Vitek, P H Gold, W Gill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
A phase I and pharmacokinetic study of tallimustine [PNU 152241 (FCE 24517)] in patients with advanced cancerG R Weiss, I Poggesi, M Rocchetti, et al.
Pageof 3